Clinical applications of phage-derived sFvs and sFv fusion proteins

Disease Markers

Volumn 16, Issue 1-2, 2000, Pages 53-62

  Chester, K A ^a   Bhatia, J ^a   Boxer, G ^a   Cooke, S P ^a   Flynn, A A ^a   Huhalov, A ^a   Mayer, A ^a   Pedley, R B ^a   Robson, L ^a   Sharma, S K ^a   Spencer, D I R ^a   Begent, R H J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ADEPT; Antibody targeting; Cancer; CEA; Fusion protein; sFv

Indexed keywords

CANCER; CONFERENCE PAPER; ESCHERICHIA COLI; HUMAN; IMMUNOGENICITY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ESCHERICHIA COLI; FILAMENTOUS BACTERIOPHAGE;

EID: 0034452868     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/672706     Document Type: Conference Paper

References (35)

1. Clinical trials of antibody therapy
2. Making antibodies by phage display technology
3. Phage libraries for generation of clinically useful antibodies
4. Taking engineered anti-CEA antibodies to the clinic
5. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
6. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines
7. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
8. Optimization of primer sequences for mouse scFv repertoire display library construction
9. Selection of phage antibodies by binding affinity. Mimicking affinity maturation
10. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography
11. Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase 1 trials
12. Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: Preparation of a genetically engineered anti- CEA single chain Fv antibody
13. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody
14. A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model
15. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments
16. Highaffinity antigen-binding by chelating-recombinant- antibodies (CRAbs)
17. A vector for expression of dimeric and chelating forms of anti-CEA scFvs
18. Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts
19. Extended glycoprotein structure of the seven domains in human carcinoembryonic antigen by X-ray and neutron solution scattering and an automated curve fitting procedure: Implications for cellular adhesion
20. Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS
21. The complete nucleotide-sequence of the pseudomonas gene coding for carboxypeptidase-G2
22. Crystal structure of carboxypeptidase G(2), a bacterial enzyme with applications in cancer therapy
23. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method
24. Novel prodrugs which are activated to cytotoxic alkylating- agents by carboxypeptidase-G2
25. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy
26. Antibody directed enzyme prodrug therapy (ADEPT): A three phase system
27. Antibody-directed enzyme prodrug therapy: A pilot clinical trial
28. First Clinical experience with ADEPT
29. Optimization of smallscale coupling of A5B7-MONOCLONAL antibody to carboxypeptidase-G2
30. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein
31. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein
32. In vivo characteristics of an engineered fusion protein for use in ADEPT
33. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT
34. Clinical applications of TNF-alpha in cancer
35. Tumour targeting using MFE-23::TNF alpha fusion protein